The company’s revenue figures for Arcalyst in the fourth quarter of 2024 and the full year were in line with expectations, indicating stable performance. Moreover, the guidance for fiscal year ...
Kiniksa reports 2024 ARCALYST revenue of $416.4 million, expecting $560-$580 million for 2025, while remaining cash flow positive. Kiniksa Pharmaceuticals has announced preliminary unaudited net ...
ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 ...
The company reported that its ARCALYST net product revenue amounted to $121.9 million for the fourth quarter and $416.4 million for the full year 2024, representing significant growth ...
On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...
ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – ...
On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...
ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth - - ARCALYST 2025 net product revenue expected to be $560 - $580 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback